Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


​ASCO GU 2017: Bladder sparing treatment in older patients

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews.

Speaker: David Miyamoto

Poster: B316 - Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients

 

  • This program is editorially independent and is financially made possible by

Related items

Congress news

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congress news

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congress news

​ASCO GU 2017: Atezolizumab in mUCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Daniel Petrylak Poster: B290 - Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study

Congress news

​ASCO GU 2017: Durvalumab in advanced UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Thomas Powles Poster: B286 - Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Congress news

ASCO GU 2017: KEYNOTE-052

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Arjun Balar Poster: B284 - Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

Congress news

ASCO GU 2017: Adjuvant radiotherapy after cystectomy

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Abhishek Solanki Poster: B369 - Adjuvant radiotherapy use after radical cystectomy in muscle-invasive bladder cancer: A survey of U.S. radiation oncologists.

Congress news

2016 GU Cancers Symposium News Program

Prof. Anthony D´Amico (Dana Faber & Harvard Cancer Institute, USA) and Prof. Nick James (Warwick Medical School, UK) discuss the highlights of the 2016 Genitourinary Cancers Symposium which took place in San Francisco from the 7th – 9th January 2016. Topics include a.o.: standard versus hypofractionated radiotherapy in prostate cancer (abstract 1 & 2) Anti Androgen Therapy after radical prostatectomy (abstract 3) update of the STAMPEDE trial (celecoxinib and zoledronic acida arms) (abstract 162) the role of circulating cell free DNA in profiling urothelial carcinoma (abstract 163) adjuvant radiation vs. chemo-radiation vs. chemotherapy alone after radical cystectomy for locally advanced bladder cancer (abstract 356)